CanSino Biologics Inc
Company Profile
Business description
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,134
Stocks News & Analysis
stocks
Cheap e-commerce share continues sales momentum
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.60 | 65.10 | -0.73% |
| CAC 40 | 8,188.87 | 19.02 | -0.23% |
| DAX 40 | 25,092.25 | 85.55 | -0.34% |
| Dow JONES (US) | 50,598.55 | 45.73 | -0.09% |
| FTSE 100 | 10,425.96 | 79.05 | -0.75% |
| HKSE | 25,006.16 | 322.07 | -1.27% |
| NASDAQ | 26,908.62 | 233.89 | 0.88% |
| Nikkei 225 | 64,693.12 | 306.29 | -0.47% |
| NZX 50 Index | 13,206.11 | 21.70 | -0.16% |
| S&P 500 | 7,562.76 | 42.40 | 0.56% |
| S&P/ASX 200 | 8,592.90 | 61.60 | -0.71% |
| SSE Composite Index | 4,098.64 | 4.91 | 0.12% |